Assessment of in vivo antimalarial activity of rifampicin, isoniazide, and ethambutol combination therapy

被引：9

作者：

Aditya, Nayak P. ^{[1
,2
]}

Patankar, Swati ^{[3
]}

Madhusudhan, Basavaraj ^{[1
,2
]}

机构：

[1] Kuvempu Univ, PG Ctr, Dept Studies Biochem, Davangere 577002, Karnataka, India

[2] Kuvempu Univ, PG Ctr, Res Ctr Nanosci & Technol, Davangere 577002, Karnataka, India

[3] Indian Inst Technol, Bio Sch, Bombay 400076, Maharashtra, India

来源：

PARASITOLOGY RESEARCH | 2010年 / 106卷 / 06期

关键词：

BIOSYNTHESIS; MALARIA; PATHWAY;

D O I：

10.1007/s00436-010-1789-y

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

The existing armament of drugs for the treatment and prevention of malaria is inadequate due to development of resistance. In addition to this due to lack of economic enticement the rate of new drug development and new drug discovery in the segment of parasitic diseases is very low as compared to the other segments. This has necessitated the better deployment and usage of existing antimalarial drugs as well as discovery of antimalarial activity of drugs which are well characterized for other diseases; these approaches help to reduce the time and cost required for new drug discovery. The present study evaluated the antimalarial activity of antituberculosis drugs rifampicin, isoniazide, and ethambutol in monotherapy and combination in Plasmodium berghei-infected mice. Animals were observed for mortality, parasite progression, and toxicity for a period of 1 month. Rifampicin + isoniazide and rifampicin + isoniazide + ethambutol treatment resulted in an overall survival rate of 60% compared to 0% in vehicle-fed animals by 4 weeks after post-infection without showing any toxicity.

引用

页码：1481 / 1484

页数：4

共 8 条

[1] INHIBITION OF RODENT MALARIA IN MICE BY RIFAMPICIN [J].

ALGER, NE ;

SPIRA, DT ;

SILVERMAN, PH .

NATURE, 1970, 227 (5256) :381-+

[2] Global fund changes tack on malaria therapy [J].

Butler, D .

NATURE, 2004, 429 (6992) :588-588

[3] Rifampicin/cotrimoxazole/isoniazid versus mefloquine or quinine plus sulfadoxine-pyrimethamine for malaria: A randomized trial [J].

Genton, Blaise ;

Mueller, Ivo ;

Betuela, Inoni ;

Casey, Gerard ;

Ginny, Meza ;

Alpers, Michael P. ;

Reeder, John C. .

PLOS CLINICAL TRIALS, 2006, 1 (08)

[4] Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs [J].

Jomaa, H ;

Wiesner, J ;

Sanderbrand, S ;

Altincicek, B ;

Weidemeyer, C ;

Hintz, M ;

Türbachova, I ;

Eberl, M ;

Zeidler, J ;

Lichtenthaler, HK ;

Soldati, D ;

Beck, E .

SCIENCE, 1999, 285 (5433) :1573-1576

[5] Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model [J].

Lenaerts, AM ;

Chase, SE ;

Cynamon, MH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3167-3168

[6] TOXIC HEPATITIS WITH ISONIAZID AND RIFAMPIN - A METAANALYSIS [J].

STEELE, MA ;

BURK, RF ;

DESPREZ, RM .

CHEST, 1991, 99 (02) :465-471

[7] ANTIMALARIAL ACTIVITY OF RIFAMPICIN INVITRO AND IN RODENT MODELS [J].

STRATH, M ;

SCOTTFINNIGAN, T ;

GARDNER, M ;

WILLIAMSON, D ;

WILSON, I .

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1993, 87 (02) :211-216

[8] A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum [J].

Waller, RF ;

Ralph, SA ;

Reed, MB ;

Su, V ;

Douglas, JD ;

Minnikin, DE ;

Cowman, AF ;

Besra, GS ;

McFadden, GI .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :297-301

← 1 →